XW0U0XB
Introduction Joints to New Technology Group 11 with Peptide Enhanced Bone Void Filler, Open Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | U Joints |
| Approach | 0 Open |
| Device | X Peptide Enhanced Bone Void Filler |
| Qualifier | B New Technology Group 11 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Joints
Introduction to joints as a body part covers delivery of a novel substance into a synovial joint space as a class, used when a New Technology agent, such as an investigational biologic or specialized lubricant, is injected to address cartilage degeneration or inflammatory joint disease. Joints are enclosed by a capsule and lined with synovium, which governs how injected material distributes and is retained, making the joint space a natural reservoir for locally acting agents. Because this code is not specific to a single joint like the knee or hip, documentation should confirm that the procedure targets joint tissue generally under the applicable New Technology group rather than a more granular articular structure. The emerging nature of these agents means outcomes tracking depends on precise, consistent code assignment across treated joints.
Approach: Open
Open approach in New Technology denotes access to the target site through a surgical incision that exposes the body part directly to view and instrumentation. It stands apart from percutaneous and endoscopic approaches, which achieve access through small punctures or existing openings rather than a deliberate surgical opening of tissue.
Device / Substance / Technology: Peptide Enhanced Bone Void Filler
Peptide Enhanced Bone Void Filler denotes use of a synthetic bone graft substitute incorporating a bioactive peptide, such as P-15, to promote osteoblast attachment and bone regeneration when packed into a skeletal defect. It is distinguished from the antibiotic-eluting and AGN1 bone void fillers by its mechanism of enhancing bone healing through peptide signaling rather than infection control or a distinct mineral composition.
Qualifier: New Technology Group 11
This qualifier designates Group 11, the most recent cohort at the time of its introduction, grouping technologies newly approved for New Technology section reporting in that fiscal year. Like every group value in this axis, it functions as an administrative marker rather than a description of the clinical intervention, which is captured elsewhere in the code. Its main point of confusion is with Group 10, the immediately preceding annual release.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.